ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023
Oral Delivery of Bioactive Glass-Loaded Core-Shell Hydrogel Microspheres for Effective Treatment of Inflammatory Bowel Disease.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Biomimetic Strategy to Fabricate Hierarchically Porous Zein Microreactors With a Hydrophobic Core-Hydrophilic Shell Architecture.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Oral hydrogel systems in lower gastrointestinal disorders: From disease-based therapy to microbiota-guided design.Materials today. Bio · 2026Review
- Microencapsulation and characterization of controlled-release intestinal drugs: a critical review.Journal of Zhejiang University. Science. B · 2026Review
- Nanomaterial-Based Strategies Targeting IL-1 Signalling in Inflammatory Bowel Disease: Therapeutic Applications and Mechanistic Insights.Journal of inflammation research · 2026Review
- Oral colon-targeted delivery of recombinant human MANF for alleviation of ulcerative colitis.International journal of pharmaceutics: X · 2025Article
- Advances and applications of gut organoids: modeling intestinal diseases and therapeutic development.Life medicine · 2025Review
- Recent Advances in the Application of Hydrogels as Drug Carriers in Inflammatory Bowel Disease: A Review.International journal of molecular sciences · 2025Review
- Inflammation Targeting-Triggered Healing Hydrogel for In Situ Reconstruction of Colonic Mucosa.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Adhesive polyelectrolyte coating through UV-triggered polymerization on PLGA particles for enhanced drug delivery to inflammatory intestinal mucosa.Journal of nanobiotechnology · 2025Article
- Stimulus-responsive smart bioactive glass composites for repair of complex tissue defects.Theranostics · 2025Review
- Ginseng polysaccharides ameliorate DSS-induced inflammatory bowel disease by regulating gut microbiota in dogs.Frontiers in veterinary science · 2025Article
- Bioactive Glass in Tissue Regeneration: Unveiling Recent Advances in Regenerative Strategies and Applications.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Dental pulp regeneration strategies: A review of status quo and recent advances.Bioactive materials · 2024Review
- Artificial mucus layer formed in response to ROS for the oral treatment of inflammatory bowel disease.Science advances · 2024Article
- Comparative Study on the Mechanism of Macrophage Activation Induced by Polysaccharides from Fresh and Dried Longan.Nutrients · 2024Article
- Advances in Hydrogel-Based Drug Delivery Systems.Gels (Basel, Switzerland) · 2024Review
- Oral Delivery of Bioactive Glass-Loaded Core-Shell Hydrogel Microspheres for Effective Treatment of Inflammatory Bowel Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 3 countries.
Funding
Abstract
Resolving inflammation and promoting intestinal tissue regeneration are critical for inflammatory bowel disease (IBD) treatment. Bioactive glass (BG) is a clinically approved bone graft material and has been shown to modulate inflammatory response, but it is unknown whether BG can be applied to treat IBD. Here, it is reported that BG attenuates pro-inflammatory response of lipopolysaccharide (LPS)-stimulated macrophages and hence reduces inflammatory damage to intestinal organoids in vitro. In addition, zein/sodium alginate-based core-shell microspheres (Zein/SA/BG) are developed for oral delivery of BG, which helps prevent premature dissolution of BG in the stomach. The results show that Zein/SA/BG protects BG from a gastric-simulated environment while dissolved in an intestinal-simulated environment. When administered to acute and chronic colitis mice model, Zein/SA/BG significantly reduces intestinal inflammation, promotes epithelial tissue regeneration, and partially restores microbiota homeostasis. These findings are the first to reveal the therapeutic efficacy of BG against IBD, which may provide a new therapeutic approach at low cost for effective IBD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.